Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

Fig. 2

Progression-free survival (a) and overall survival (b) in patients with brain metastases treated with gefitinib, erlotinib, or afatinib; overall survival in patients with different numbers of brain metastases (c), different epidermal growth factor receptor gene mutation types (d), concomitant liver metastases (e), and different M stages (f); overall survival in patients with and without radiotherapy (g) and with and without surgical excision (h); and overall survival in patients with different locations of disease progression (i)

Back to article page